Related Experiment Video
Updated: Jun 13, 2026
08:55
Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence
Published on: November 2, 2014
CA125 in ovarian cancer
Nathalie Scholler1, Nicole Urban
1Center for Research on Early Detection & Cure of Ovarian Cancer School of Medicine, University of Pennsylvania Biomedical Research Building (BRB) II/III, Suite 1355 421 Curie Blvd, PA 19104-6080, USA. naths@mail.med.upenn.edu
Biomarkers in Medicine
|May 19, 2010
Summary
CA125 antigen is used for ovarian cancer screening but has limitations. Research shows CA125 may predict early ovarian cancer and has therapeutic potential, with anti-CA125 treatments suggesting survival benefits.
Area of Science:
- Biochemistry
- Immunology
- Oncology
Background:
- The CA125 antigen, discovered 25 years ago, is utilized in the USA for ovarian cancer screening in high-risk women.
- Despite its use, CA125 exhibits limited sensitivity and specificity for ovarian cancer detection.
- Emerging research suggests CA125's potential as a predictive marker for pre-invasive ovarian carcinoma.
Purpose of the Study:
- To review the evolving understanding of CA125 antigen, its quantification methods, and its potential roles in ovarian cancer and immunology.
- To explore CA125's structure, function, and therapeutic implications.
Main Methods:
- Review of scientific literature on CA125 antigen, MUC16 gene, and related assays.
- Analysis of findings regarding CA125's role in ovarian cancer prediction and immunological functions.
- Examination of clinical trial data for anti-CA125 therapies.
Main Results:
- Quantification methods for CA125 have advanced to sensitive double-determinant ELISA assays.
- The CA125 gene (MUC16) encodes a complex glycoprotein with suggested immunological functions.
- CA125 may induce materno-fetal tolerance and interacts with receptors like mesothelin and galectin-1.
- Anti-CA125 therapies are well-tolerated and show potential for survival benefit in clinical trials.
Conclusions:
- CA125 remains a clinically relevant marker for ovarian cancer screening, with potential for early detection.
- The complex structure and immunological functions of CA125 present therapeutic opportunities.
- Targeting CA125 offers a promising strategy for ovarian cancer treatment with potential survival advantages.
